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Abstract: Long QT syndrome refers to a characteristic 
abnormality of the electrocardiogram and it is associated 
with a form of ventricular tachycardia known as torsade-
de-pointes and sudden arrhythmic death. It can occur as 
part of a hereditary syndrome or can be acquired usually 
because of drug administration. Here we review recent 
genetic, molecular and cellular discoveries and outline 
how they have furthered our understanding of this disease. 
Specifically we focus on compound mutations, genome 
wide association studies of QT interval, modifier genes and 
the therapeutic implications of this recent work.
Keywords: cardiac arrhythmia; HERG; KCNQ1; long QT 
syndrome; potassium channel; SCN5A; sodium channel; 
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Introduction
Sudden cardiac death (SCD) is a major health care problem 
and claims up to 300 000 lives per year in the USA alone 
(Deo and Albert, 2012). It occurs most commonly in older 
individuals with ischaemic heart disease however, SCD 
also occurs in younger patients under the age of 35. In 
this group the causes are more heterogeneous including a 
number of unique syndromes largely with a genetic basis 
(Deo and Albert, 2012). The hereditary long QT syndromes 
are one such entity and lethal arrhythmia is present in 
the absence of structural heart disease (Moss and Kass, 
2005; Schwartz et  al., 2012). The QT interval refers to a 
measurement made from the surface ECG and reflects the 
time taken for repolarisation of the cardiac action poten-
tial (Figure  1A). It is rate dependent with shortening at 
higher heart rates and thus is rate corrected using a variety 
of algorithms of which Bazett’s correction is the one most 
commonly used [QTc = QT/sqrt(R-R)] though with poor justi-
fication (Karjalainen et al., 1994). By itself a prolonged QT 
interval is not harmful but it can lead to a particular form 
of ventricular tachycardia known as  torsade de pointes and 
this can degenerate into ventricular  fibrillation and death 
(Figure 1B). Hereditary and acquired forms of the disease 
are recognised with the latter particularly associated with 
administration of a wide range of different drugs including 
non-cardiac medications.
The incidence of the hereditary long QT syndrome 
is approximately 1 in 2000 births and two clinical syn-
dromes are described (Schwartz et al., 2009). The first is 
Romano-Ward syndrome which is inherited in an autoso-
mal dominant fashion and is relatively common (Ward, 
1964; Romano, 1965). The rarer Jervell-Lange-Nielsen syn-
drome is an autosomal recessive disease and is addition-
ally associated with hearing loss. It is also severer with a 
substantially prolonged QTc and cardiac arrest at a young 
age (Jervell and Lange-Nielsen, 1957). Classic genetic 
approaches in families with large pedigrees revealed the 
causative genes. Fifteen genetic loci and genes have been 
linked with hereditary long QT syndromes (Table  1). In 
most modern series a mutation is identified in 80% of 
patients. LQT1 and LQT2 evenly account for close to 90% 
of all gene positive cases with LQT3 accounting for 8% and 
the other causes being rare (Splawski et al., 2000). Indeed 
some of these have only been described in a single family 
or proband. It is worth noting that in two of the LQT syn-
dromes, though they are very rare, they have a series of 
other disease manifestations. In Anderson’s syndrome 
(LQT7) there are skeletal abnormalities and periodic 
paralysis in addition to long QT and malignant ventricu-
lar arrhythmias (Plaster et al., 2001; Tristani-Firouzi et al., 
Q1:
Gene names 
are set italic 
font – please 
check and 
indicate 
where italic 
should be 
applied 
throughout
2      S.C. Harmer and A. Tinker: Genetics and mechanisms in long QT syndromes
2002). In Timothy syndrome (LQT8) the extra-cardiac 
features include webbing of fingers and toes, autism, 
intermittent hypoglycaemia and immune impairment 
(Splawski et al., 2004).
The QT interval is related to the action potential dura-
tion and thus it was not surprising that the LQT genes 
encoded ion channels governing excitability. KCNQ1 
(Kv7.1\KvLQT1) (LQT1) is a shaker like voltage-gated K+ 
channel subunit that together with the β subunit KCNE1 
(LQT5) underlies the IKs current (Barhanin et  al., 1996; 
Sanguinetti et  al., 1996b). HERG (KCNH2, Kv11.1) (LQT2) 
together with perhaps KCNE2 (LQT6) generates the IKr 
repolarising K+ current (Sanguinetti et al., 1995; Trudeau 
et  al., 1995; Abbott et  al., 1999). SCN5A (LQT3) is the 
cardiac sodium current and CACN1C (Cav1.2, LQT8) the 
L-type calcium current (Wang et al., 1995). KCNJ2 (LQT7) 
underlies some if not all IK1 and is mutated in  Anderson’s 
syndrome (Tristani-Firouzi et al., 2002). All of these genes 
can lead to the Romano-Ward syndrome whilst only muta-
tions in KCNQ1 (LQT1) and KCNE1 (LQT5) can lead to 
Jervell-Lange-Nielsen syndrome (Tyson et al., 1997).
There are other interesting cardiac clinical features. 
Cardiac arrest in LQT1 tends to be provoked by exercise 
or stress and swimming is a particular trigger. In LQT2 
it is sudden often auditory events such as being woken 
from sleep by an alarm or an unexpected telephone call 
(Schwartz et  al., 2001). In LQT3 arrhythmic events tend 
to occur during sleep. There are also mutations in SCN5A 
that can lead to both LQT3 and Brugada syndrome (Makita 
et al., 2008). Thus the hereditary long QT syndromes have 
traditionally been viewed as a classic monogenic genetic 
disorder with mutations in a number of different genes 
leading to the clinical disorder.
Disease mechanisms
Mutation type and location
As detailed above the majority of long QT syndrome 
cases are caused by mutations of the genes encoding the 
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Figure 1: LQTS mutations lead to delayed ventricular myocyte repolarisation, a prolonged QT interval, and can under certain situations 
precipitate arrhythmic events.
(A) Mutations in the major LQTS causing genes (LQT1-15) act, in general, to result in either a delayed or reduced potassium efflux (red line). 
This delay in ventricular myocyte repolarisation is manifest on a surface electrocardiogram (ECG) as a prolonged QT interval. The ‘T’ wave 
on an ECG corresponds to the repolarisation phase of the heart. The end of the ‘T’ wave is indicated by the dashed line. When corrected for 
heart rate the QT interval is considered prolonged if  > 450 ms. (B) In LQTS patients a prolonged QT interval can act, alongside other triggers, 
to precipitate a particular characteristic type of arrhythmia called torsade de pointes (TdP). TdP can further degenerate into ventricular 
 fibrillation, syncope and sudden death.
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outward potassium currents IKs and IKr carried by KCNQ1 
and HERG (LQT1 and LQT2), respectively. In both proteins 
there are a large number of described mutations which 
are distributed throughout the N- and C-termini and 
transmembrane domains with some evidence of cluster-
ing around the pore (Splawski et  al., 2000;  Kapplinger 
et  al., 2009). The majority of mutations are missense 
(~85%) with frame-shift and nonsense mutations being 
rarer. In the majority of cases with missense mutations 
an abnormal protein will be generated and then there 
are a number of potential mechanisms that could be 
operative. The mutant protein could traffic to the plasma 
membrane and when resident there either not function 
at all or have some abnormality in its normal gating. 
Alternatively there may be a cellular trafficking deficit: 
the protein may be unstable in the plasma membrane or 
be retained within the cell. There is substantial evidence 
for both mechanisms and for certain mutations multiple 
mechanisms can be operative (Sanguinetti et al., 1996a; 
Chouabe et al., 1997; Franqueza et al., 1999; Huang et al., 
2001; Moss and Kass, 2005). There are correlations with 
mutation location and severity of disease for LQT1 and 
LQT2. In LQT1 and LQT2 mutations in the transmem-
brane regions of KCNQ1 and pore region of HERG, respec-
tively have been shown to increase the risk of arrhythmia 
(Moss et al., 2002, 2007).
Defective channel function
Mutations in KCNQ1 and HERG (LQT1 and 2) can cause 
dysfunction by inhibiting the ability of these channels 
to open/gate properly. These defects result in a loss-of 
function and reduce the level of IKs or IKr current. In con-
trast, the sodium channel mutations in LQT3 are gain 
of function mutations and result in persistent inward 
sodium current. One of the first studied mutations was 
a three amino acid deletion (KPQ) in the III-IV linker 
region (Bennett et  al., 1995): a region that is important 
for voltage dependent inactivation (Catterall, 2012). This 
mutation was subsequently engineered into the mouse 
genome and replicated many aspects of the human 
disease (Nuyens et al., 2001; Head et al., 2005). The study 
of a large number of other mutations confirmed changes 
in biophysical properties of the current engendered by the 
mutation led to excessive and persistent inward current 
as a general feature of the condition (Wang et al., 1995; 
Wang et  al., 1996). In an analogous manner in Timothy 
syndrome the G406R mutation in CACN1C results in 
increased calcium current due to a loss of inactivation 
(Splawski et al., 2004).
Defective channel trafficking
The aberrant trafficking of channel complexes appears to 
play a major role in both LQT1 and LQT2 disease pathogen-
esis (Zhou et al., 1999; Ficker et al., 2000; Paulussen et al., 
2002; Wilson et al., 2005; Dahimene et al., 2006). In fact, 
in LQT2 it has been suggested to be the most important 
mechanism (Anderson et al., 2006, 2014). Of the mutations 
in HERG or KCNQ1 that cause defective trafficking the vast 
majority result in retention of the channel protein in endo-
plasmic reticulum (ER) (Ficker et al., 2000; Wilson et al., 
2005). In one case of LQT1 the Y111C mutation enhanced 
the degradation of the channel by the proteasome (Peroz 
et al., 2009).
Frameshifts, premature termination codons 
and nonsense mediated decay
Premature termination codon generating mutations may 
potentially result in the production of shorter truncated 
channel proteins. However, we are now more aware of 
nonsense mediated decay as a mechanism that can lead to 
RNA degradation of nonsense mutations prior to protein 
translation (Frischmeyer and Dietz, 1999). There is evi-
dence for this with HERG though it has not been explicitly 
examined for KCNQ1 to our knowledge (Gong et al., 2007). 
The mutations will lead to haploin insufficiency in the 
heterozygous form and complete loss of function in the 
homozygous form. In LQT1 nonsense mutations have been 
associated with a lower arrhythmic risk when compared 
to missense mutations (Ruwald et al., 2015). Interestingly, 
frameshift mutations appear to have an equivalent risk 
to missense mutations, perhaps because some of these 
may be in-frame or may be less prone to nonsense medi-
ated decay resulting in the production of mutant protein 
(Ruwald et al., 2015).
Additional disease mechanisms in RWS
There is another important factor to consider in domi-
nant LQT syndromes. Potassium channels, such as 
KCNQ1, HERG and KCNJ2, are tetrameric proteins 
and thus can be subject to dominant negative effects 
( Herskowitz, 1987). This refers to the significant func-
tional impairment that can arise from the co-expression 
of a normal and mutant allele. For example, if the inclu-
sion of a single mutant allele in a potassium channel 
tetramer inactivates function then this will lead to loss 
of over 90% of current from binomial considerations of 
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the dominant negative effect in addition to the haplo-
insufficiency. Recessive LQT syndrome does occur as 
in JLNS and we and others have addressed the ques-
tion of why the KCNQ1 and KCNE1 mutations do not 
have consequences in the carriers. It is notable that the 
KCNQ1 mutations are often nonsense. The assembly of 
potassium channels into tetramers is often determined 
by well-defined domains (Tinker, 2002). In the case of 
KCNQ1 the domain is present in the C-terminus and 
thus premature truncation of the protein before this 
point would mean that the mutant protein is unable 
to interact with the wild-type channel (Chouabe et  al., 
1997; Schmitt et al., 2000; Huang et al., 2001). Even mis-
sense mutations such as R594Q were proposed to act in 
this fashion (Schmitt et  al., 2000; Huang et  al., 2001). 
However, as we discussed above nonsense mediated 
decay is likely to be the predominant mechanism with 
nonsense mutations and this would lead to pure haplo-
insufficiency in heterozygotic mutation carriers. This in 
our view is the more probable explanation though this 
needs to be examined experimentally.
Auxiliary subunits
In addition to the main pore forming subunit there are 
also mutations in the auxiliary subunits KCNE1 and 
KCNE2. KCNE1 profoundly modifies the function of 
KCNQ1 and is well accepted as contributing with KCNQ1 
to the molecular equivalent of IKs (Barhanin et al., 1996; 
Sanguinetti et  al., 1996b). KCNE2 has been suggested 
to perform an analogous modulatory role for HERG but 
this is much more controversial (Abbott et al., 1999). We 
looked at the behaviour of a number of LQT5 causing 
KCNE1 mutants and found a mixture of mechanisms 
including abnormal gating and impaired assembly 
(Harmer et al., 2010). Trafficking impairment was rela-
tively modest for the mutants we studied but has been 
reported by other groups (Krumerman et al., 2004). This 
said there is good evidence that the KCNE subunits may 
be much more promiscuous in their interactions with 
ion channels and this has largely not been factored 
into discussions of the potential pathogenic mecha-
nism (McDonald et  al., 1997; Decher et  al., 2003; Wu 
et al., 2006; Abbott et al., 2007; Roepke et al., 2008; Nof 
et al., 2011). There is also evidence that mutations in a 
sodium channel subunit SCN4B might cause severe long 
QT syndrome (LQT10) (Medeiros-Domingo et al., 2007). 
Expression of the SCN4B missense mutation, L179F, 
with SCN5A led to a persistent inward sodium current 
as in LQT3.
Human induced pluripotent stem cell-derived 
cardiomyocyte (hiPSC-CM) models of LQTS
Cardiomyocytes derived from human induced pluripotent 
stem cells (iPSCs) is a rapidly emerging technology that 
was first used in 2009 (Zhang et  al., 2009). Soon after, 
Moretti and colleagues published the first hiPSC-CM 
model of LQTS (Moretti et al., 2010). Fibroblasts from two 
LQT1 patients carrying the KCNQ1-G569A (R190Q) muta-
tion and two healthy controls were reprogrammed to gen-
erate iPSCs. These iPSCs were then differentiated towards 
cardiomyocytes and their electrophysiological properties 
analysed. The action potentials (APs) of both atrial-like 
and ventricular-like hiPSC-CMs were found to be pro-
longed and the peak tail current density of the IKs current 
was reduced by 75% in cells carrying the KCNQ1-G569A 
mutation when compared to the healthy controls. In 2011, 
two groups published iPSC models of LQT2 and the hiPSC-
CMs generated from LQT2 patients had prolonged APs 
and reduced IKr current density (Itzhaki et al., 2011; Matsa 
et al., 2011). The cardiac features of LQT8 (Timothy syn-
drome) were also modelled in the same year by Yazawa 
and colleagues (Yazawa et al., 2011). hiPSC-CMs with the 
CACNA1C-G1216A (G406R) mutation had larger L-type 
calcium currents and delayed calcium channel inactiva-
tion. The alterations in calcium channel properties also 
led to abnormal intracellular calcium handling, prolonged 
calcium transients, and ventricular-like action potentials 
that were three times longer than those seen for hiPSC-
CMs from unrelated controls (Yazawa et al., 2011). An LQT3 
causing mutation (SCNA5-5387_5389insTGA (1795insD) 
this mutation is also associated with the Brugada syn-
drome) was studied using iPSC technology in 2012 (Davis 
et al., 2012). The LQT3 hiPSC-CMs had prolonged APs and 
increased levels of persistent ‘late’ sodium current when 
compared to control cells from an unaffected control 
patient (Davis et  al., 2012). In general, iPSC-CM based 
modelling of LQTS has largely recapitulated the expected 
electrophysiological phenotypes based on patient ECG 
morphology, animal models, and prior heterologous cell 
expression studies (see Hoekstra et al., 2012).
Although iPSC-CM based models of LQTS are excit-
ing there exist some concerns about their ability to fully 
model the electrophysiological consequences of disease 
causing mutations. In particular, iPSC-CMs are immature 
in their nature, both electrophysiologically and morpho-
logically (Knollmann, 2013). Electrophysiologically, the 
APs produced from hiPSC-CMs can be very heterogene-
ous in nature and these cells lack robust expression of the 
inward rectifying current IK1. The lack of IK1 is of particu-
lar concern as it leads to depolarised resting membrane 
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potentials, increased spontaneous activity, and a greater 
dependence on other currents for repolarisation (in par-
ticular IKr) (Doss et al., 2012; Lieu et al., 2013). Approaches 
that lead to the maturation of iPSC-CMs towards a more 
adult phenotype are actively being pursued. Recently, in 
an effort to counter the heterogenous nature of the APs 
produced by hiPSC-CMs gene editing has been used to 
generate isogenic stem-cell ‘pairs’ for LQT2 and LQT3 
disease modelling (Bellin et al., 2013; Zhang et al., 2014). 
This approach allows researchers to investigate the effect 
of a particular mutation under the same cellular genetic 
background. Isogenic stem-cell ‘pairs’ should also offer 
exciting opportunities for studying the role played by 
complex genetics and LQTS disease modifiers such as 
single nucleotide polymorphisms (see below and Munroe 
and Tinker, 2015). The human and patient specific nature 
of iPSC-CM technology provides a great deal of scope 
for developing therapies to better understand, treat and 
manage LQTS. Indeed, as an example, a number of dif-
ferent LQTS subtype iPSC models have already been 
screened for their propensity to drug-induced arrhyth-
mia (Liang et al., 2013). Approaches to rescue/reverse the 
LQT2 disease phenotype, such as pharmacological based 
rescue of defective channel trafficking (Mehta et al., 2014) 
and small interfering RNA (siRNA) mediated ‘knockdown’ 
of mutant hERG allele expression (Matsa et  al., 2014), 
appear promising.
Physiological triggers of arrhythmia in LQTS
As described above it is clear that arrhythmia can be pro-
voked by exercise in particular swimming in LQT1 and 
sudden arousal in LQT2 (Schwartz et al., 2001). That swim-
ming in particular should provoke arrhythmia in LQT1 is 
interesting and suggests that both sympathetic and par-
asympathetic coactivation is especially proarrhythmic 
(Shattock and Tipton, 2012). The common thread linking 
these is activation of the adrenergic system. During exer-
cise the action potential and QT interval shorten with 
increasing heart rate and a key factor in this is the increase 
in IKs current. This occurs for two reasons. The first is that 
current accumulates at high rates as deactivation kinetics 
are slow and at faster rates, between each action potential, 
the channel fails to fully deactivate (Stengl et al., 2003). A 
second reason is that increased sympathetic drive during 
exercise activates β-adrenergic receptors increasing the 
current levels. This regulation is probably much more 
important than is commonly appreciated as IKs blocking 
drugs have modest effects on action potential duration 
in isolated ventricular myocytes but the effects are much 
more pronounced on the QT interval in vivo (Volders et al., 
2003). It should be borne in mind that in general there 
is a substantial amount of ‘repolarisation reserve’ due 
to the presence of IKr and IK1 in addition to IKs in cardiac 
ventricular myocytes. This likely explains in general terms 
the variable penetrance of disease causing mutations and 
variable effects of QTc prolonging drugs (Lengyel et  al., 
2004; Jost et al., 2005; Nagy et al., 2009).
The effects of sympathetic nervous drive on IKs is a 
classic pathway mediated via protein kinase A activation 
and direct channel phosphorylation on the  N-terminus 
at S27 (Marx et  al., 2002). There have been reports of 
particular mutations in LQT1 and LQT5 that impair PKA 
dependent phosphorylation and activation of the channel 
(Kurokawa et al., 2003; Heijman et al., 2012; Bartos et al., 
2014). The A341V KCNQ1 mutation is particularly inter-
esting. It is a founder mutation in large South African 
pedigrees and is generally very severe in clinical expres-
sion (Brink et al., 2005). However, when studied initially 
in heterologous systems it was found to have relatively 
mild functional impairment (Wang et  al., 1999). This 
paradox was resolved when the mutation was found to 
lead to severely abrogated PKA dependent regulation that 
also occurred in heteromultimeric channel populations 
mimicking RWS (Heijman et al., 2012). Furthermore, the 
activation requires association of KCNQ1 with KCNE1 and 
the microtubule network and is dependent on a protein 
kinase A anchoring protein (AKAP) yotiao\AKAP9 (Marx 
et al., 2002; Kurokawa et al., 2003; Nicolas et al., 2008). 
A specific phosphodiesterase may also be part of this 
complex and yotiao\AKAP9 itself needs to be phospho-
rylated by PKA (Chen et al., 2005; Terrenoire et al., 2009). 
Mutations in yotiao\AKAP9 have been associated with 
the long QT syndrome (LQT11) but only in a single family 
to our knowledge (Chen et  al., 2007). Other cardiac K+ 
currents such as HERG can also be regulated by protein 
kinases but the physiological significance of this is less 
clear (Sroubek and McDonald, 2011; Shu et al., 2013). It 
is not clear as to why LQTS patients are predisposed to 
 torsade-de-pointes as opposed to other forms of ventricu-
lar tachycardia. It seems the generation of early afterdepo-
larisations is important with this occurring particularly in 
the endo and mid-myocardium promoting re-entry (Akar 
et al., 2002).
Rare causes of LQTS
There are a series of other causes of LQT syndrome which 
are rare. These include mutations in Ankyrin (LQT4) 
(Mohler et al., 2003), caveolin-3 (LQT9) (Vatta et al., 2006), 
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α-1-syntrophin (LQT12) (Wu et al., 2008; Ueda et al., 2008), 
KCNJ5 (LQT13) (Wang et al., 2013) and calmodulin 1 and 
2 (LQT14 and LQT15) (Crotti et al., 2013). Plausible cases 
can be made for these proteins in modulating cardiac ven-
tricular excitability and being potentially arrhythmogenic 
however, the pedigrees and number of families are often 
limited.
Summary
Thus there has been substantial work on the mechanism 
by which the known mutations potentially influence myo-
cardial ventricular excitability. However, recently there 
have been some interesting genetic findings that modify 
our understanding of disease pathogenesis and manifes-
tations in the individual. We consider compound muta-
tions, genome wide association studies on the QT interval 
and modifier genes.
Compound mutations increase 
arrhythmic risk
In the inherited long QT syndromes compound muta-
tions are common with a frequency of close to 10% and 
intriguingly are associated with a more malignant course 
and higher arrhythmia burden (Schwartz et  al., 2003; 
 Westenskow et  al., 2004; Tester et  al., 2005; Itoh et  al., 
2010;  Giudicessi and Ackerman, 2013). They can occur 
within the same gene for example two different mutations 
on different alleles in the same gene or two mutations in 
different gene, e.g. KCNQ1 and KCNH2. Westenskow and 
colleagues investigated the first scenario (Westenskow 
et al., 2004). When a single mutation was expressed in a 
heterozygous manner recapitulating a potential RWS phe-
notype, they found only a small dominant negative effect. 
However, when expressed in compound form there was a 
striking reduction in IKs current density. The conclusion 
was that the severe clinical phenotype was accounted for 
by the additive effects of the single mutations on the IKs 
current (Westenskow et al., 2004). We have recently inves-
tigated this issue and asked are there any other patho-
genic factors that may account for the pronounced disease 
manifestations (Harmer et  al., 2014). Our study showed 
that failure of membrane delivery of KCNQ1 contributed 
significantly to the disease mechanism.  Specifically, we 
identified a class of mutation that are severely retained 
but do not have a dominant negative effect on the traf-
ficking of wild-type KCNQ1. For the combinations A178T/
K422fs39X, T391I/Q530X and A525T/R518X there was an 
additive effect impairing channel  trafficking as well as 
other functional effects that would exacerbate the pheno-
type (Harmer et al., 2014).
For the large majority of compound heterozygous 
KCNQ1 mutations reported, the probands present with 
autosomal recessive long QT syndrome and their hearing 
is normal. However, this is not the case in all families 
and there are situations where deafness occurs with two 
different KCNQ1 mutations present on different alleles 
( Giudicessi and Ackerman, 2013). There appears to be 
threshold effect where preservation of a tenth of the 
current is sufficient to rescue hearing. For example, in 
consanguineous Arabian families a homozygous reces-
sive mutation was identified in the first intron in a splice 
acceptor site. This led to a significantly reduced but not 
totally absent KCNQ1 transcript (Bhuiyan et  al., 2008). 
This idea is in keeping with our recent study. The com-
pound effects of A525T/R518X and A178T/K422fs39X lead 
to ~85% loss of current but the mutations do not result in 
deafness (Harmer et al., 2014).
Complex genetics
At the population level the QT interval is a heritable trait 
and as such is amenable to the analysis of its genetic 
architecture using genome wide association studies 
(GWAS). The imputation of a particular gene as being 
causative in the trait is more problematic than in classic 
monogenic disorders (Munroe and Tinker, 2015). The 
linked loci often contain signals that are in introns or 
large intergenic regions and in linkage disequilibrium 
with other genes. However, a number of such studies 
have been undertaken and the results are informative. 
In some cases the loci clearly implicated known genes 
encoding proteins involved in cardiac repolarisation 
and in the hereditary long QT syndromes (Newton-Cheh 
et al., 2009; Pfeufer et al., 2009; Arking et al., 2014). In 
general, the effect size of a locus is relatively small and 
is about 3–5 ms. The most strongly associated signals 
were related to the nitric oxide synthase adaptor protein 
(NOS1AP) (Arking et al., 2006; Newton-Cheh et al., 2009; 
Pfeufer et al., 2009; Arking et al., 2014). At the time of the 
initial discovery it was unknown as to the role of NOS1AP 
in cardiac repolarisation. Functional studies showed 
that together with nitric oxide synthase it was a poten-
tial regulator of calcium channel function (Chang et al., 
2008). Specifically the protein complex inhibited L-type 
calcium function shortening repolarisation. Kapoor and 
colleagues identified the potential causative SNP as a 
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noncoding polymorphism within an enhancer region of 
the NOS1AP leading to increased expression of the tran-
script (Kapoor et  al., 2014). Furthermore, they showed 
that NOS1AP localised to the intercalated disc and that 
overexpression of NOS1AP protein in neonatal rat ven-
tricular myocytes shortened the action potential and 
also perhaps surprisingly increased conduction velocity. 
A recent study of over 75,000 individuals identified loci 
particularly associated with myocyte calcium handling 
(Arking et al., 2014). Finally, the functional study of the 
ring finger protein, RNF207, another protein associated in 
GWAS for QT interval showed that it interacted with HERG 
(Roder et al., 2014). Overexpression of RNF207 led to an 
increase of HERG protein, membrane localisation and 
currents some of which was also dependent on coexpres-
sion of heat shock protein 70.
It has been appreciated for a number of years that 
particularly in Romano-Ward syndrome the penetrance of 
the disease is highly variable in mutation carriers (Priori 
et al., 1999). The explanation for this is still obscure but 
there have been some recent developments. The idea of 
variable ‘repolarisation reserve’ in different individuals 
has been used to explain why some develop drug induced 
long QT (Sesti et al., 2000). A similar concept could apply 
in the hereditary long QT syndrome but the practicalities 
of finding sufficiently large pedigrees meant this was dif-
ficult to explore experimentally. The convergence of study 
of the large family pedigrees carrying the KCNQ1 A341V 
mutation and candidate loci identified in GWAS enabled 
the design of credible experiments. This has enabled 
the identification of loci linked to NOS1AP and AKAP9 
as potential modifier genes that can affect penetrance 
(Tomas et al., 2010; de Villiers et al., 2014). There are also 
suggestions that the KCNE1 D85N polymorphic variant 
may be more common in LQT syndrome probands (Nishio 
et al., 2009). Polymorphisms in the 3′ untranslated region 
of KCNQ1 also appear to modulate disease severity in 
patients with LQT1 (Amin et al., 2012). This study identi-
fied three SNPs that modulate disease severity and pro-
vides evidence that they modulate the expression of the 
allele (e.g. mutant or wild-type) on which they reside and 
therefore alter the balance of wild-type to mutant allele 
expression (Amin et  al., 2012). Very recently SNPs that 
have been previously linked to QT-interval (as discussed 
earlier), (NOS1AP SNPs and a common KCNQ1 SNP) 
have also been identified as modifiers of disease sever-
ity in LQT2 patients (Kolder et  al., 2015). Interestingly, 
the effects of these SNPs on the QT interval are larger in 
the LQT2 patients than the normal population and this is 
presumably due to their already reduced repolarisation 
reserve (Kolder et al., 2015).
Genetics and drug-induced long QT 
syndrome
A wide variety of different pharmacophores, including 
agents developed for diseases outside the cardiac arena, 
can prolong the QT interval and precipitate torsade-
de-pointes and this presents a significant challenge 
for the pharmaceutical industry (Witchel and Hancox, 
2000; Fermini and Fossa, 2003). The agents seem share 
a common mechanism of action namely blocking of the 
HERG channel (Sanguinetti et  al., 1995). HERG uniquely 
seems to possess an accommodating binding pocket that 
allows interaction with many different chemical struc-
tures (Mitcheson et  al., 2000). Despite the advances in 
ion channel structure determination we still do not have 
a high resolution structure of HERG to analyse this fully 
at the molecular level. Currently, there has been some 
success in the use of predictive tools based on quantita-
tive structure-activity relationships that assess a com-
pound’s potential for HERG block (Aronov, 2008; Nikolov 
et al., 2014). The occurrence of drug induced long QT and 
 torsade-de-pointes with a given drug is relatively rare 
and it is not clear why only some individuals develop the 
problem. In some cases the precipitant might be a known 
event such as inter-current illness leading to a fall in serum 
K+ concentration or co-administration of another inter-
acting drug. However, even with this taken into account 
specific individuals seem predisposed to drug induced 
long QT. The first idea was that this may be a forme-fruste 
or concealed form of hereditary LQTS revealed by drug 
administration. However, whilst it is possible to identify 
individual cases where this is the probable explanation, 
on balance the data seem to indicate that this is rare (prob-
ably 10% or less of cases) (Napolitano et al., 2000; Yang 
et al., 2002; Paulussen et al., 2004). A more likely scenario 
from recent studies is that the genes underlying popula-
tion variation in QT account for the predisposition. For 
example, single nucleotide polymorphisms in the NOS1AP 
locus was increased in prevalence in a group of individu-
als with drug induced long QT (Jamshidi et al., 2012).
Clinical implications
How does improved knowledge of the genetic and molecu-
lar basis of long QT syndrome and attendant mechanisms 
impact on patient management? The mainstays of man-
agement are β blockers, implantable cardiac defibrillators 
and left cervical sympathectomy (Schwartz et  al., 2012). 
There is evidence that implantable cardiac defibrillators 
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are overused with the attendant complications from a com-
bination of over diagnosis and over treatment (Gaba et al., 
2015). In the latest European Society of Cardiology guide-
lines genetic screening can help in algorithms for both 
diagnosis and management (Priori et  al., 2015). Specifi-
cally, the identification of a particular mutation as causa-
tive in a patient means that a family can be screened and 
if carriers but asymptomatic given general advice to avoid 
certain drugs and environmental triggers (Schwartz et al., 
2001). There has been interest in gene specific therapy, for 
example sodium channel blockers such as ranolazine in 
LQT3, and such studies are ongoing (Moss et  al., 2008). 
The use of genetic information is likely to increase as next 
generation DNA sequencing technologies are brought to 
bear in clinical diagnostic services (Li et al., 2013).
An appreciation of the pathogenesis of the mutations 
involved in genetic disease has led to some promising 
approaches in cystic fibrosis. VX-770 activates the cystic 
fibrosis transmembrane conductance regulator (CFTR) 
and improves the function of specific mutant channels 
(G551D) which traffic normally but are unable to gate 
appropriately. This agent has been shown to be effective 
in patients improving a number of markers of disease pro-
gression (Ramsey et al., 2011). However, in the majority of 
cases of cystic fibrosis the CFTR channel contains a dele-
tion of phenylalanine at position 508 resulting in reten-
tion in the endoplasmic reticulum and degradation (Ward 
et al., 1995; Seibert et al., 1997). Critically, if the channel 
is allowed to escape to the plasma membrane then it 
can form an adequate chloride conductance (Drumm 
et  al., 1991). Chaperone like drugs have been developed 
to do this (VX-809) and in patient trials improve clini-
cal parameters when given in combination with VX-770 
(Wainwright et al., 2015). The important conclusion from 
these studies is that it may be possible to design muta-
tion specific agents that ameliorate the underlying defect. 
In LQT2 there are data that the modulation of trafficking 
by E-4031 and ranolazine might be efficacious for a sig-
nificant number of different mutations (Smith et al., 2013; 
Anderson et al., 2014). E-4031 is a HERG blocker but has a 
relatively short half-life and the effects on trafficking are 
much more prolonged than the blocking action (Smith 
et al., 2013). This is highly speculative yet in the long QT 
syndromes but illustrates that such a strategy may be fea-
sible. Indeed, novel and specific channel KCNQ1 openers 
have been identified (Mattmann et al., 2012).
Another molecular approach is the promotion of 
read-through of nonsense mutations. This occurs with a 
number of aminoglycosides but newer agents have been 
developed that are better tolerated by patients (Welch 
et  al., 2007). PTC124 is in development for Duchenne 
muscular dystrophy and cystic fibrosis though there are 
some doubts as to its efficacy (Kerem et  al., 2008; Auld 
et  al., 2009; McElroy et  al., 2013; Mullard, 2014). This 
approach has been explored for LQT2 and sodium channel 
nonsense mutations (Yao et al., 2009; Teng et al., 2009) 
and we have also examined such a strategy for LQT1 and 
found that whilst full-length channel expression occurred 
there were also alterations in the biophysical properties 
of the resultant channels presumably resulting from the 
replacement of the stop codon with a harmful amino acid 
(Harmer et al., 2012).
Conclusions
There have been substantial advances in the genetics and 
underlying disease mechanisms of the long QT syndrome 
over the last 10 years. The use of findings from genome 
wide association studies especially has enabled some 
understanding of modifier genes responsible for vari-
able penetrance and predisposition in the drug induced 
long QT syndrome. In the future the understanding of the 
pathogenic mechanism may enable mutation specific per-
sonalised therapy for patients addressing the underlying 
cellular defects.
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